Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIN-2 trial in high-risk early breast cancer
2011-005214-11Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Apr 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, docetaxel, paclitaxel and trastuzumab in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Invasive disease-free survival. Started Apr 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005214-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005214-11.